| Shen, Feng |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
| Not yet recruiting | 3 | 165 | RoW | TQB3454 tablets, TQB3454 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Biliary Carcinoma | 12/26 | 12/26 | | |
NCT05913336: A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU |
|
|
| Recruiting | 1/2 | 20 | RoW | Remimazolam Tosilate | Jiangsu HengRui Medicine Co., Ltd. | Sedation in the ICU | 11/23 | 11/23 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
NCT05292443: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer |
|
|
| Withdrawn | N/A | 300 | RoW | Observation | Geneplus-Beijing Co. Ltd., Eastern Hepatobiliary Surgery Hospital | Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma | 03/23 | 03/23 | | |
| Bao, Leilei |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
